Dot blot assay showed an increase in Aβ1‐42 content during the progression of the disease (Fig 6B,F; ANOVA, P < 0.001; Tukey post hoc Control vs AD‐II‐III, P < 0.05; Tukey post hoc Control vs AD‐IV‐VI, P < 0.001) that significantly correlated with the levels of β1‐integrin (r = 0.4, P = 0.03) and NOX2 (r = 0.49, P = 0.014) (Fig 6G,H, respectively) in the cortical areas of human samples. Here, CYBB is linked to Alzheimer disease.